Houston Concierge Medicine and Cardio Diagnostics partner for early cardiovascular detection

Houston Concierge Medicine will add the Epi+Gen CHD test to its Executive Health Program

Heart disease the leading cause of death in the United States for both men and women, as well as most racial and ethnic groups. In fact, that one person dies every 36 seconds from cardiovascular disease in this country, so catching it early could literally be the difference between life and death. 

To help identify those at risk for coronary heart disease, Cardio Diagnostics Holdings, a precision cardiovascular diagnostics company, has developed the Epi+Gen CHD test, which combines epigenetics, genetics, high-throughput computing, and AI.

The test, which can be taken at home, provides personalized insights based on genetic and epigenetic DNA biomarkers, which are unique to that individual, for personalized treatment. 

Now the company is expanding its reach through a partnership announced on Wednesday with Houston Concierge Medicine, a medical practice serving executives and health-forward consumers in Houston, which will use the Epi+Gen CHD test in its Executive Health Program.

When a patient requests Epi+Gen CHD test from one of Cardio's telemedicine providers, they are asked to fill out an assessment to determine their eligibility. Once their sample is processed, their results will be reviewed by a clinician who will help tailor a personalized prevention plan, and the patient will be able to schedule a private, telemedicine consultation with that prescribing clinician. 

In addition to their genetics, Epi+Gen CHD also measures the patient's epigenetic DNA biomarkers, which takes into account how environment and lifestyle can influence their heart health. The company analyzes their unique DNA biomarker information through its proprietary Artificial Intelligence algorithms to determine the patient's likelihood of having a coronary heart disease event in the next three years.

“We are excited to partner with Dr. Burzynski and the Houston Concierge Medicine,” Dr. Meesha Dogan, Chief Executive Officer and co-founder of Cardio Diagnostics, said in a statement.

“We’ve seen many innovative and agile providers in the concierge medicine space lead the adoption curve with respect to Epi+Gen CHD. The use of epigenomics to drive precise and personalized health decisions for their busy patients is being driven forward by organizations like Houston Concierge Medicine.”

For Houston Concierge Medicine, this partnership will allow them to expand their executive physicals, which can help identify and address potential health risks before they become serious. The aim is to reduce both medical costs and absenteeism over time. 

“At Houston Concierge Medicine, we’re committed to providing our patients with best-in-class diagnostic solutions. And since heart disease is top of mind for so many of our clients who work in fast-paced, stressful environments, the addition of Epi+Gen CHD will enable our practice to provide patients with objective and non-invasive tests to determine their risk for heart disease. We’re proud to partner with Cardio Diagnostics,” said Dr. Greg Burzynski, founder and CEO of Houston Concierge Medicine, in a statement

(Image source: cardiodiagnosticsinc.com)